Details for Patent: 12,661,359

« Back to Dashboard

Which drugs does patent 12,661,359 protect, and when does it expire?

Patent 12,661,359 protects REZDIFFRA and is included in one NDA.

This patent has ten patent family members in ten countries.

Summary for Patent: 12,661,359

Title:	Therapeutic combinations of rosuvastatin and resmetirom for the treatment of liver disorders or lipid disorders
Abstract:	The present disclosure provides a combination therapy for treating a liver disease or disorder and/or a lipid disease or disorder in a subject in need thereof. Specifically, the combination therapy comprises administration of rosuvastatin and resmetirom to a subject in need thereof.
Inventor(s):	Rebecca Taub
Assignee:	Madrigal Pharmaceuticals Inc
Application Number:	US18/263,546
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 12,661,359

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Madrigal	REZDIFFRA	resmetirom	TABLET;ORAL	217785-001	Mar 14, 2024		RX	Yes	No	12,661,359					TREATMENT OF ADULTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) IN PATIENTS RECEIVING ROSUVASTATIN
Madrigal	REZDIFFRA	resmetirom	TABLET;ORAL	217785-002	Mar 14, 2024		RX	Yes	No	12,661,359					TREATMENT OF ADULTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) IN PATIENTS RECEIVING ROSUVASTATIN
Madrigal	REZDIFFRA	resmetirom	TABLET;ORAL	217785-003	Mar 14, 2024		RX	Yes	Yes	12,661,359					TREATMENT OF ADULTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) IN PATIENTS RECEIVING ROSUVASTATIN

International Family Members for US Patent 12,661,359

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2022213405
Canada	3206392
China	116847847